Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2020 - 2025)
Prelude Therapeutics' (PRLD) quarterly Non-Current Deffered Revenue came in at $1.8 million in Q4 2025, up 497.34% quarter-over-quarter from $301000.0 in Q4 2020.
Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2020 - 2025) Analysis & Trends
Prelude Therapeutics has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $1.8 million for Q4 2025.
- Non-Current Deffered Revenue for Q4 2025 came in at $1.8 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $1.8 million (changed N/A YoY), and the FY2025 annual result was $1.8 million, changed N/A from the prior year.
- Non-Current Deffered Revenue came in at $1.8 million for Q4 2025 at Prelude Therapeutics, up from $301000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $1.8 million in Q4 2025 to a low of $1.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prelude Therapeutics | 358.14 Mn | 213.54 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.80 Mn |
| Dec 31, 2020 | 301,000.00 |